Studies on Plasma Thromboxane B₂ Levels in Patients with Kawasaki Disease; as an Indicator of Coronary Aneurysm Formation

Publisher Website

1 June 1983

journal article
Published by Wiley in Pediatrics International

Vol. 25 (2), 230-236
https://doi.org/10.1111/j.1442-200x.1983.tb01691.x

Abstract

No abstract available

Keywords

KAWASAKI DISEASE
THROMBOXANE B2
CORONARY ANEURYSM
AND INCREASED PLATELET AGGREGABILITY. THROMBOXANE A2 IS READILY METABOLIZED TO THE INACTIVE THROMBOXANE B2 IN THE INITIAL STAGE OF KAWASAKI DISEASE. PLASMA THROMBOXANE B2 LEVELS IN NORMAL SUBJECTS WERE 0.28+‐ 0.19 NG/ML (MEAN +‐ SD
N=10). PLASMA THROMBOXANE B2 LEVELS IN PATIENTS WITH KAWASAKI DISEASE BEFORE TREATMENT
WERE 0.33 +‐ 0.21 NG/ML (MEAN +‐ SD
N=27). PATIENTS WITH CORONARY ANEURYSM HAD MARKEDLY INCREASED PLASMA THROMBOXANE B2 LEVELS (2.16+‐ 0.89 NG/ML
N=5). ELEVATION OF PLASMA THROMBOXANE B2 LEVELS INDICATES THAT THERE IS THE POSSIBILITY OF ENDOTHELIAL INJURY AND ANEURYSM FORMATION. ALSO
PLASMA THROMBOXANE B2 LEVELS IMMEDIATELY DECREASED AFTER THE START OF TREATMENT WITH ASPIRIN OR FLURBIPROFEN. ON THE OTHER HAND
THERE WAS NO SIGNIFICANT EVEIDENCE THAT THE PRODUCTION OF THROMBOXANE A2 WAS INHIBITED BY STEROID TREATMENT. THEREFORE
THE TREATMENT WITH ASPIRIN IN THE INITIAL STAGE IS MORE EFFECTIVE IN PREVENTING ANEURYSM FORMATION. THESE RESULTS SUGGEST THAT KAWASAKI DISEASE IS CLOSELY ASSOCIATED WITH PROSTGLANDIN METABOLISM INCLUDING THROMBOXANE A2.

Cited by 9 articles